Skip to main content
Premium Trial:

Request an Annual Quote

Horizon Discovery EGFR Multiplex cfDNA Reference Standard

Horizon Discovery has launched a new cell line-derived EGFR Multiplex cell-free DNA reference standard, which allows labs and assay developers to optimize, validate and routinely monitor performance of PCR assays, NGS tests, and other novel liquid biopsy tests designed to detect EGFR mutations in cfDNA.

The new referene standard covers ten of the most clinically relevant mutations that predict responsiveness to EGFR tyrosine kinase inhibitors, including T790M, L858R, C797S and E746-A750del. Additionally, variants have been carefully selected to represent a mix of different mutation types that can be challenging for laboratories to detect.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.